Sourced directly from manufacturers
Supported by UK-based clinical team with monthly check-ins
Access to Obesity Specialist Dietitian
Fully UK GPhC Registered Pharmacy, trusted by over 90,000 patients
GLP-1 (glucagon-like peptide-1) receptor agonists are prescription medicines used in weight management. Some GLP-1 medicines are currently available as injections following assessment by a clinician.
Oral GLP-1 tablets are tablet formulations being developed and studied for weight management. These medicines work by mimicking the GLP-1 hormone, which can help regulate appetite and food intake.
Treatment suitability, availability and prescribing decisions are determined by a clinician following an appropriate consultation.
Tablet-based weight loss treatments
Contain a GLP-1 receptor agonist (the same active ingredient as Wegovy)
Taken once daily, rather than once weekly by injection
Clinically tested with results comparable to injectable options
A non-injectable alternative for those who prefer not to use a pen
Easier to fit into everyday life for some people
No refrigeration or injection equipment required
The same clinically-led approach, in a simpler format
Two large clinical trials give us the best picture so far. Here's what happened when real patients took oral GLP-1 tablets alongside diet and lifestyle support.
average body weight lost over 64 weeks
In a study of 307 adults – that's roughly 1 in 4 losing 20% or more of their body weight.
average body weight lost over 74 weeks
In a study of 3,127 adults – over half lost at least 10% of their body weight.
* Averages from clinical trials in controlled settings alongside diet and lifestyle support. Individual results will vary.
* The two trials used different designs and durations and cannot be directly compared with each other.
* Both treatments are not yet available in the UK. Availability is subject to regulatory approval. Both expected in 2026.
Oral GLP-1 tablets and injectable GLP-1 treatments are both effective, clinically-proven options. The right choice depends on your personal preferences and circumstances. Here is a quick comparison:
* Averages from clinical trials in controlled settings alongside diet and lifestyle support. Individual results will vary.
* The two trials used different designs and durations and cannot be directly compared with each other.
* Both treatments are not yet available in the UK. Availability is subject to regulatory approval. Both expected in 2026.
We will keep you informed with everything you need to know. Here is what being on our list means for you:
Be the first to know: get notified the moment oral weight loss tablets are licensed for use in the UK.
Clinician-led care: as with all Morrisons Clinic treatments, you will receive ongoing support from our UK-registered clinical team
No need to keep checking: we will do the monitoring and reach out when there is a meaningful update
Trusted by thousands of patients: Morrisons Clinic is a GPhC-regulated pharmacy
Expert guidance: our clinicians will help you understand whether oral weight loss treatment is right for you when it becomes available
Like all medicines, oral GLP-1 tablets can cause side effects. Most are digestive and tend to be mild to moderate, often settling down as your body adjusts during the first few weeks of treatment.
*This information is based on phase 3 clinical trial data and US prescribing information.
This is not a complete list of side effects. Always consult a qualified clinician before starting treatment.
Our clinical team have been closely following developments in oral GLP-1 research. Here are the latest articles from the Phlo Clinic weight loss advice hub:
You will receive a confirmation that we have your details
We will email you when there is a significant regulatory update
In the meantime, our clinical team are on hand if you have any questions about your weight loss options
If you decide you would like to start treatment now, you can begin a free online assessment for injectable Wegovy or Mounjaro at any time
1. Wharton S, et al. Oral semaglutide 25mg in adults with overweight or obesity (OASIS 4). N Engl J Med. 2025;393(11):1077–1087. doi:10.1056/NEJMoa2500969
2. Wharton S, et al. Orforglipron, an oral GLP-1 receptor agonist for obesity (ATTAIN-1). N Engl J Med. 2025;393(18):1796–1806. doi:10.1056/NEJMoa2511774
3. Novo Nordisk. Wegovy (semaglutide) tablet US prescribing information. Plainsboro, NJ: Novo Nordisk Inc.; 2025. 4.Eli Lilly and Company. Foundayo (orforglipron) US prescribing information. Indianapolis, IN: Eli Lilly; 2026.
4. Eli Lilly and Company. Foundayo (orforglipron) US prescribing information. Indianapolis, IN: Eli Lilly; 2026.
Morrisons Clinic
Unit 1 Fifth Street
Trafford Park
Manchester
England
M17 1JX
Dennis Ouko
MRPharmSGPhC
Registration Number: 2205052
Phlo Technologies Ltd
